Reni Benjamin, an analyst at Raymond James & Associates Inc., downgraded Kite to hold on May 8, saying the commercial prospects for axi-cel in non-Hodgkin lymphoma had been largely priced into the stock. When Maxim Group LLC analyst Jason McCarthy cut his recommendation to hold last month, he wa
